Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HLA-A2 Positive Cells Present”

24 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 24 results

Testing effectiveness (Phase 2)Study completedNCT00509288
What this trial is testing

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Who this might be right for
MelanomaSkin Cancer
National Cancer Institute (NCI) 24
Early research (Phase 1)Study completedNCT00112229
What this trial is testing

Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients

Who this might be right for
Melanoma
Centre Hospitalier Universitaire Vaudois 29
Testing effectiveness (Phase 2)Ended earlyNCT04093323
What this trial is testing

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Who this might be right for
HLA-A2 Positive Cells PresentRefractory Melanoma
Roswell Park Cancer Institute 1
Early research (Phase 1)Study completedNCT04842513
What this trial is testing

Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma

Who this might be right for
Glioblastoma Multiforme of Brain
University Hospital Tuebingen 15
Early research (Phase 1)Study completedNCT00003184
What this trial is testing

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Providence Cancer Center, Earle A. Chiles Research Institute
Testing effectiveness (Phase 2)Study completedNCT00194714
What this trial is testing

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Who this might be right for
HER2/Neu PositiveHLA-A2 Positive Cells PresentStage IV Breast Cancer+1 more
University of Washington 22
Testing effectiveness (Phase 2)Ended earlyNCT01670994
What this trial is testing

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Altor BioScience 6
Early research (Phase 1)Active Not RecruitingNCT03132792
What this trial is testing

AFPᶜ³³²T in Advanced HCC

Who this might be right for
Hepatocellular CancerAFP Expressing Tumors
Adaptimmune 45
Testing effectiveness (Phase 2)Study completedNCT01326871
What this trial is testing

ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Who this might be right for
Transitional Cell Carcinoma of BladderUrethra CancerUreter Cancer+1 more
Altor BioScience 68
Early research (Phase 1)Study completedNCT01095848
What this trial is testing

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

Who this might be right for
Ovarian NeoplasmsBreast NeoplasmsProstatic Neoplasms
ImmunoVaccine Technologies, Inc. (IMV Inc.) 23
Testing effectiveness (Phase 2)Study completedNCT00306514
What this trial is testing

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Who this might be right for
Melanoma
Cytos Biotechnology AG
Testing effectiveness (Phase 2)Ended earlyNCT01308294
What this trial is testing

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients

Who this might be right for
Melanoma
Centre Hospitalier Universitaire Vaudois 16
Testing effectiveness (Phase 2)Ended earlyNCT01625260
What this trial is testing

ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer
Altor BioScience 12
Very early researchEnded earlyNCT02774291
What this trial is testing

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Who this might be right for
HLA-A2 Positive Cells PresentMetastatic Malignant NeoplasmMetastatic Malignant Neoplasm in the Brain
Albert Einstein College of Medicine 3
Testing effectiveness (Phase 2)Study completedNCT00306566
What this trial is testing

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Who this might be right for
Malignant Melanoma
Cytos Biotechnology AG
Early research (Phase 1)Active Not RecruitingNCT02869217
What this trial is testing

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Who this might be right for
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive PatientsSynovial SarcomaMelanoma+5 more
University Health Network, Toronto 22
Testing effectiveness (Phase 2)Study completedNCT00651703
What this trial is testing

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Who this might be right for
Malignant Melanoma
Cytos Biotechnology AG 21
Testing effectiveness (Phase 2)Study completedNCT00003895
What this trial is testing

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Who this might be right for
Recurrent MelanomaStage IA MelanomaStage IB Melanoma+6 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)UnknownNCT04634747
What this trial is testing

Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

Who this might be right for
Metastatic Triple-Negative Breast Carcinoma
OncoPep, Inc. 53
Large-scale testing (Phase 3)Looking for participantsNCT06472245
What this trial is testing

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Who this might be right for
Patients With Non-Small Cell Lung Cancer
OSE Immunotherapeutics 363
Load More Results